Physician profile
Michael Tsadyk
NPI 1194212902
$1,153.57
in general payments reported to CMS, 2019-2025
21 companies · $761 in 2025
The $761 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.52 · 2022: $44.53 · 2023: $25.61 · 2024: $266 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $256.26 | 2025 | |
| Intra-Sana Laboratories | $178.69 | 2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Pfizer INC. | $96.05 | 2021-2025 | |
| Amgen INC. | $94.58 | 2024-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $61.34 | 2025 | Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $58.68 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.95 | 2025 | Xifaxan |
| Exact Sciences Corporation | $42.97 | 2025 | The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $36.48 | 2024-2025 | Mounjaro, Kisunla |
| Currax Pharmaceuticals LLC | $34.58 | 2025 | Contrave |
| Novo Nordisk INC | $31.93 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $26.67 | 2025 | Opsumit |
| Merck Sharp & Dohme LLC | $25.61 | 2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Dexcom, INC. | $24.59 | 2025 | Dexcom G6 Transmitter |
| Philips North America LLC | $23.61 | 2025 | Ecc Solutions |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $22.06 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.66 | 2025 | |
| Optinose US, INC. | $17.84 | 2025 | |
| Viiv Healthcare Company | $17.44 | 2025 | Apretude |
| Paratek Pharmaceuticals, INC. | $15.95 | 2024 | Nuzyra |
| Phadia US INC. | $14.63 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tsadyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.